KURA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Kura Oncology Inc (KURA) is not a strong buy for a beginner investor with a long-term strategy at this moment. Despite positive analyst ratings and improving financial metrics, the lack of significant trading signals, insider selling, and no recent news catalysts suggest waiting for a clearer entry point.
The MACD histogram is positive at 0.149 and expanding, indicating a bullish trend. RSI is at 70.899, which is neutral, and moving averages are converging, showing no strong directional bias. The stock is trading near its resistance level of R1: 8.547, with pre-market price at 8.555, suggesting limited immediate upside.
Analysts maintain a Buy/Overweight rating with price targets significantly higher than the current price. Financial performance shows improvement in net income and EPS YoY. Upcoming earnings on February 25, 2026, could act as a catalyst if results exceed expectations.
Insider selling has increased by 178.01% in the last month, signaling potential lack of confidence from company insiders. No recent news or event-driven catalysts. Hedge funds remain neutral, and there are no significant trading trends.
In Q3 2025, revenue remained flat YoY at $20.75M. However, net income improved by 36.23% YoY to -$74.12M, and EPS increased by 34.92% YoY to -0.85. Gross margin remains strong at 100%. While losses are narrowing, the company is still unprofitable.
Analysts are positive on the stock. BofA recently lowered its price target slightly to $29 from $30 but maintained a Buy rating, citing limited impact from upcoming earnings. Barclays raised its price target to $28 from $11, citing ziftomenib approval. Both targets are significantly above the current price.
